Patents by Inventor Jordan Tang
Jordan Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240038351Abstract: Systems and methods for implementing machine-learning models for ovarian stimulation is described herein. In some variations, a computer-implemented method may include optimizing an ovarian stimulation process may include receiving patient-specific data associated with a patient, and predicting an egg outcome for the patient for each of a plurality of treatment options for an ovarian stimulation process based on at least one predictive model and the patient-specific data, where the at least one predictive model is trained using prior patient-specific data associated with a plurality of prior patients.Type: ApplicationFiled: June 29, 2023Publication date: February 1, 2024Inventors: Kevin LOEWKE, Paxton MAEDER-YORK, Melissa TERAN, Mark LOWN, Arielle Sarah ROTHMAN, Veronica Isabella NUTTING, Michael FANTON, Jordan TANG
-
Patent number: 11735302Abstract: Systems and methods for implementing machine-learning models for ovarian stimulation is described herein. In some variations, a computer-implemented method may include optimizing an ovarian stimulation process may include receiving patient-specific data associated with a patient, and predicting an egg outcome for the patient for each of a plurality of treatment options for an ovarian stimulation process based on at least one predictive model and the patient-specific data, where the at least one predictive model is trained using prior patient-specific data associated with a plurality of prior patients.Type: GrantFiled: March 29, 2022Date of Patent: August 22, 2023Assignee: Alife Health Inc.Inventors: Kevin Loewke, Paxton Maeder-York, Melissa Teran, Mark Lown, Arielle Sarah Rothman, Veronica Isabella Nutting, Michael Fanton, Jordan Tang
-
Publication number: 20220399091Abstract: Systems and methods for implementing machine-learning models for ovarian stimulation is described herein. In some variations, a computer-implemented method may include optimizing an ovarian stimulation process may include receiving patient-specific data associated with a patient, and predicting an egg outcome for the patient for each of a plurality of treatment options for an ovarian stimulation process based on at least one predictive model and the patient-specific data, where the at least one predictive model is trained using prior patient-specific data associated with a plurality of prior patients.Type: ApplicationFiled: March 29, 2022Publication date: December 15, 2022Inventors: Kevin LOEWKE, Paxton MAEDER-YORK, Melissa TERAN, Mark LOWN, Arielle Sarah ROTHMAN, Veronica Isabella NUTTING, Michael FANTON, Jordan TANG
-
Patent number: 9096541Abstract: Proteases such as memapsin-1 are import enzymes, playing roles in a variety of diseases including diabetes. The inventors have developed inhibitors of memapsin 1 and methods of use therefore in the treatment of disease.Type: GrantFiled: March 11, 2013Date of Patent: August 4, 2015Assignees: Oklahoma Medical Research Foundation, Purdue Research FoundationInventors: Jordan Tang, Xiangping Huang, Deborah Downs, Arun K. Ghosh
-
Publication number: 20140066488Abstract: Proteases such as memapsin 2 are important enzymes, playing roles in a variety of diseases including Alzheimer's Disease. The inventors have developed inhibitors of memapsin 2 and methods of use therefore in the treatment of disease.Type: ApplicationFiled: August 28, 2013Publication date: March 6, 2014Applicants: Purdue Research Foundation, Oklahoma Medical Research FoundationInventors: Jordan Tang, Venkateswararao Kalapala, Arun K. Ghosh
-
Publication number: 20130261052Abstract: Proteases such as memapsin-1 are import enzymes, playing roles in a variety of diseases including diabetes. The inventors have developed inhibitors of memapsin 1 and methods of use therefore in the treatment of disease.Type: ApplicationFiled: March 11, 2013Publication date: October 3, 2013Applicant: Oklahoma Medical Research FoundationInventors: Jordan Tang, Xiangping Huang, Deborah Downs
-
Publication number: 20120100564Abstract: Aspartic proteases such as mempasin-2 are import enzymes, playing roles in a variety of diseases. The inventors have developed a model to predict the cleavage sites and preferences for memapsin 2 substrates.Type: ApplicationFiled: August 30, 2011Publication date: April 26, 2012Inventors: Jordan Tang, Xiaoman Li, Jean Hartsuck
-
Patent number: 7989597Abstract: This application pertains to antibodies which specifically bind to immunogenic memapsin 2?-secretase peptides for use in the treatment of Alzheimer's disease and memapsin 2?-secretase disorders. The application also pertains to immunogenic compositions comprising memapsin 2?-secretase peptides and uses thereof.Type: GrantFiled: June 22, 2009Date of Patent: August 2, 2011Assignee: Oklahoma Medical Research FoundationInventors: Wan-Pin Chang, Jordan Tang
-
Publication number: 20110183891Abstract: The present invention describes a previously unknown interaction between secreted aspartic proteases (SAPs), including SAPs 4-6 of Candida albicans, and integrins on host cells. The SAPs secure entry into the host cell through RGD-like binding motifs and subsequently induce apoptosis, thereby clearing the way for systemic infection. The invention thus provide a new target for therapeutic intervention and describes peptides and antibodies that inhibit the action of SAPs in this context, including their interaction with integrins.Type: ApplicationFiled: December 14, 2010Publication date: July 28, 2011Inventors: Jordan Tang, Hao Wu
-
Publication number: 20100015154Abstract: This application pertains to antibodies which specifically bind to immunogenic memapsin 2?-secretase peptides for use in the treatment of Alzheimer's disease and memapsin 2?-secretase disorders. The application also pertains to immunogenic compositions comprising memapsin 2?-secretase peptides and uses thereof.Type: ApplicationFiled: June 22, 2009Publication date: January 21, 2010Inventors: Wan-Pin Chang, Jordan Tang
-
Publication number: 20080176939Abstract: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.Type: ApplicationFiled: August 1, 2007Publication date: July 24, 2008Applicants: CoMentis, Inc., The Board of Trustees of the University of Illinois, Oklahoma Medical Research Foundation, Purdue Research FoundationInventors: Arun K. Ghosh, Nagaswamy Kumaragurubaran, Chunfeng Liu, Thippeswamy Devasamudram, Hui Lei, Lisa Swanson, Sudha Ankala, Jordan Tang, Geoffrey Bilcer
-
Publication number: 20080021196Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1).Type: ApplicationFiled: June 14, 2007Publication date: January 24, 2008Applicants: The Board of Trustees of the University of Illinois, Oklahoma Medical Research FoundationInventors: Jordan TANG, Arun Ghosh
-
Publication number: 20070248599Abstract: Alzheimer's disease (AD) is characterized by the accumulation of amyloid-? peptide (A?) in the brain. A? is derived from amyloid precursor protein (APP) by ?- and ?-secretases. Apolipoprotein E receptor 2 (ApoER2) is a cell-surface receptor for apolipoprotein E. This study shows that ApoER2 interacts with X11?/? proteins and that APP forms association with ApoER2 in the presence of X11s. Significantly, ApoE stimulates the production of A?, and ApoE4 produced more A? than ApoE2 or ApoE3, correlating with previous studies showing that individuals with the ApoE4 polymorphism were more prone to development of AD. Thus, ApoE binding to ApoER2 on cell surface stimulates the generation of A? from APP. Antagonists that interfere with the ApoE-ApoER2 interaction are proposed for the treatment of AD.Type: ApplicationFiled: February 16, 2007Publication date: October 25, 2007Inventor: Jordan Tang
-
Publication number: 20070117793Abstract: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.Type: ApplicationFiled: August 9, 2006Publication date: May 24, 2007Applicants: Zapaq, Inc., The Board of Trustees of the University of Illinois, Oklahoma Medical Research Foundation, Purdue Research FoundationInventors: Arun Ghosh, Nagaswamy Kumaragurubaran, Chunfeng Liu, Thippeswamy Devasamudram, Hui Lei, Lisa Swanson, Sudha Ankala, Jordan Tang, Geoffrey Bilcer
-
Publication number: 20070092517Abstract: The present invention provides novel methods of reducing memapsin 2 ?-secretase activity in a subject, decreasing levels of ?-amyloid peptide in the brain of a subject, treating Alzheimer's disease and/or reducing the size and/or number of ?-amyloid plaques in the brain of a subject. The methods may include the step of administering an effective amount of truncated memapsin 2 protein, anti-truncated memapsin 2 antibody, and/or nucleic acid encoding a truncated memapsin 2 protein or anti-truncated memapsin 2 antibody. The present invention also provides related pharmaceutical compositions and uses thereof.Type: ApplicationFiled: August 9, 2006Publication date: April 26, 2007Applicant: Oklahoma Medical Research FoundationInventors: Wan Chang, Deborah Downs, Jordan Tang
-
Publication number: 20060234944Abstract: Compounds inhibit memapsin 2 ?-secretase activity and selectively inhibit memapsin 2 ?-secretase activity relative to memapsin 1 ?-secretase activity. The compounds are employed in methods to inhibit memapsin 2 ?-secretase activity, in the treatment of Alzheimer's disease, in the inhibition of hydrolysis of a ?-secretase site of a ?-amyloid precursor protein and to decrease ?-amyloid protein in in vitro samples and in mammals. Proteins of memapsin 2 associated with compounds of the invention are crystallized.Type: ApplicationFiled: October 23, 2002Publication date: October 19, 2006Applicants: Oklahoma Medical Reseach Foundation, The Board of Trustees of the University of IllinoisInventors: Arun Ghosh, Jordan Tang, Geoffrey Bilcer, Wanpin Chang, Lin Hong, Gerald Koelsch, Jeff Loy, Robert Turner III
-
Publication number: 20050239684Abstract: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.Type: ApplicationFiled: September 17, 2004Publication date: October 27, 2005Applicants: Zapaq, Inc., The Board of Trustees of the University of Illinois, Oklahoma Medical Research FoundationInventors: Arun Ghosh, Jordan Tang, Hui Lei, Thippeswamy Devasamudram, Chunfeng Liu, Geoffrey Bilcer
-
Patent number: 6225103Abstract: A previously unknown aspartic protease capable of cleavage of proteins by hydrolysis, referred to herein as “napsin”, has been cloned from a human liver library. Two cDNA clones have been cloned, sequenced and expressed. These encode isozymes of the protease, referred to as “napsin A” and “napsin B”. The gene has also be obtained and partially sequenced. A process for rapid purification of the enzyme using immobilized petpstatin has also been developed, and enzyme isolated from human kidney tissue. Polyclonal antibodies to the enzymes have been made which are also useful for isolation and detection of the enzyme. Similarities to other aspartic proteases, especially cathepsin D, establish the usefulness of the enzyme in diagnostic assays as well as as a protease. Either or both the amount or type of napsin expressed in a particular tissue can be determined using labelled antibodies or nucleotide probes to the napsin.Type: GrantFiled: November 20, 1997Date of Patent: May 1, 2001Assignee: Oklahoma Medical Research FoundationInventors: Gerald Keolsch, Xinli Lin, Jordan Tang